LIGAND PHARMACEUTICALS INC — Director's Dealing 2021

Jun 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-06-04

Reporting Person: Aryeh Jason (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-04	Common Stock	A	630	$0.0	Acquired	68664	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-04	Non-Qualified Stock Option (right to buy)	$115.39	A	3269	Acquired	2031-06-04	Common Stock (3269)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	51594	Indirect
Common Stock	5025	Indirect

Footnotes

F1: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

F2: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.

F3: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.